Haematologica EWOG-MDS website
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Rooden, C.
Right arrow Articles by Huisman, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Rooden, C.
Right arrow Articles by Huisman, M.
Haematologica, Vol 89, Issue 2, 201-206
Copyright © 2004 by Ferrata Storti Foundation


Journal Article

The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis

CJ Van Rooden, FR Rosendaal, AE Meinders, JA Van Oostayen, FJ Van Der Meer, and MV Huisman

Department of General Internal Medicine. Leiden University Medical Center (LUMC), Leiden, the Netherlands.

BACKGROUND AND OBJECTIVES: The purpose of this study was to assess the incidence of central venous catheter (CVC)-related thrombosis and the contribution of two common inherited coagulation disorders (factor V Leiden, prothrombin G20210A mutation) to this complication in a large hospital population. DESIGN AND METHODS: In a prospective setting, patients were assessed daily for signs and symptoms suggestive of thrombosis. Routine Doppler-ultrasound was performed weekly in all patients until CVC removal. Doppler-ultrasound examinations were stored on videotape and assessed by two blinded observers. In the case of clinically suspected thrombosis the physicians followed routine diagnostic and therapeutic procedures. The presence of factor V Leiden and prothrombin G20210A mutation and other potential risk factors were assessed in all patients. RESULTS: In 252 consecutive patients the cumulative incidence of-CVC related thrombosis was 30% (clinically manifested thrombosis: 7%). The relative risk of factor V Leiden or prothrombin G20210A mutation for thrombosis was 2.7 (CI95% 1.9 to 3.8). In addition, a personal history of venous thrombosis was associated with CVC-related thrombosis, whereas the severity of thrombosis was affected by the absence of anticoagulants and the presence of cancer. INTERPRETATION AND CONCLUSIONS: Thrombosis is frequently observed after central venous catheterization. Common inherited abnormalities in blood coagulation contribute substantially to CVC-related thrombosis. In view of physicians' reluctance to prescribe prophylactic anticoagulant treatment in vulnerable patients, a priori determination of common inherited and acquired risk factors may form a basis to guide these treatment decisions.


This article has been cited by other articles:


Home page
haematolHome page
S. Navarro, P. Medina, Y. Mira, A. Estelles, P. Villa, F. Ferrando, A. Vaya, R. M. Bertina, and F. Espana
Haplotypes of the EPCR gene, prothrombin levels, and the risk of venous thrombosis in carriers of the prothrombin G20210A mutation
Haematologica, June 1, 2008; 93(6): 885 - 891.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
R. S. Boersma, K.-S. G. Jie, A. Verbon, E. C. M. van Pampus, and H. C. Schouten
Thrombotic and infectious complications of central venous catheters in patients with hematological malignancies
Ann. Onc., March 1, 2008; 19(3): 433 - 442.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
G. Ferretti, E. Bria, A. Felici, P. Carlini, D. Giannarelli, M. Ciccarese, P. Papaldo, A. Fabi, A. Gelibter, and F. Cognetti
Catheter-associated thrombosis: thromboprophylaxis for cancer patients who carry factor V Leiden?
Ann. Onc., March 1, 2006; 17(3): 528 - 529.
[Full Text] [PDF]


Home page
ASH Education BookHome page
P. L. Bockenstedt
Management of Hereditary Hypercoagulable Disorders
Hematology, January 1, 2006; 2006(1): 444 - 449.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. N. Levine
In Reply:
J. Clin. Oncol., October 1, 2005; 23(28): 7244 - 7244.
[Full Text] [PDF]




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.